Background. Age is a known risk factor for recurrence in women with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS). We explored the relationship between age, other risk factors, and recurrence. Methods. Using a prospectively maintained database of DCIS patients undergoing BCS from 1978 to 2010, the association of age and recurrence risk was analyzed using Kaplan-Meier estimates, multivariable analysis, and competing risk multivariable analysis. Results. Overall, 2996 cases were identified. Median follow-up for those without recurrence was 75 months; 732 were followed for C10 years, and 363 (12 %) had recurrence [192 (53 %) with and without radiation therapy. Using competing risk multivariable analysis, the effect of age on invasive recurrence was empirically stronger than for DCIS recurrence. Ten-year invasive recurrence was 16 and 6.5 % in women \40 years of age and women C40 years of age, respectively. Only 0.6 % of the population ultimately developed distant disease; those \40 years of age constituted 4.7 % (141/2996) of the population, but 21 % (4/19) of those developed distant disease. Conclusions. The risk of recurrence of DCIS decreases with age. This effect is particularly strong at the extremes of age and is independent of other clinicopathologic factors. The oldest women are at low risk of recurrence, while the youngest women have a higher overall, and especially invasive, recurrence rate, although mortality remains low. These findings should be incorporated into risk/benefit discussions of treatment options.
Epidemiology, and End Results (SEER) registry found an increased risk of breast cancer mortality for those \35 years of age 11 ; however, the relationship between age and recurrence across the full spectrum of age, as well as the interaction between age and other clinicopathological and treatment factors, has not been fully elucidated. The goal of this study was to explore the association of age with ipsilateral locoregional recurrence, both in situ and invasive, and development of distant disease.
METHODS
Following Institutional Review Board approval, the outcomes of DCIS patients who underwent BCS at Memorial Sloan Kettering Cancer Center from 1978 to 2010 were analyzed from a prospectively maintained database. Bilateral cases of DCIS in patients with either synchronous (n = 30) or metachronous (n = 29) lesions were abstracted as separate cases.
Patients were grouped and analyzed according to age at the time of surgery (\40, 40-49, 50-59, 60-69, 70-79 or C80 years). Other factors analyzed were family history of breast cancer (defined as one or more first-or second-degree family member), presentation (radiological or clinical), nuclear grade (low/intermediate or high), necrosis, number of excisions required (B2 or C3), margin status [positive/close (B2 mm) or negative ([2 mm)], use of adjuvant RT and endocrine therapy, and treatment time period (B1998 or C1999). 15 The primary endpoint was time to first recurrence, categorized as DCIS recurrence or invasive recurrence. DCIS recurrence was defined as ipsilateral breast recurrence of DCIS without invasion, and invasive recurrence was defined as first recurrence as ipsilateral invasive breast cancer, ipsilateral axillary nodal recurrence without ipsilateral breast recurrence, or, in a single patient, distant recurrence in the absence of any ipsilateral recurrence or contralateral diagnosis of breast carcinoma. Time to event was defined as the interval between definitive surgery and the date of first recurrence.
A secondary endpoint was development of distant disease at any time, in the absence of contralateral invasive breast cancer. Differences in patient characteristics by age were assessed using the v square test. Five-and 10-year KaplanMeier recurrence estimates by age were calculated for the entire population, as well as the cohorts with and without RT. Multivariable Cox regression analysis was used to assess the relationship between age and recurrence after adjustment for clinicopathological and treatment factors. Competing risk analysis was used to assess the risk of invasive or in situ recurrence according to age univariately, and competing risk multivariable analysis was used to adjust for other factors. Women in whom the type of recurrence (invasive or DCIS) was not known were excluded from the competing risk analysis. All analyses were performed in SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA, and R version 3.1.1 [https://www.rproject.org/]).
RESULTS
Overall, 2996 cases of DCIS managed with BCS from 1978 to 2010 were identified. Characteristics of the entire population and the cohorts stratified by decade of age at the time of surgery are shown in Table 1 . The median patient age was 57 years (range , and the distribution of the study population by age is shown in electronic supplementary Fig. 1 .
The median follow-up was 75 months (range 0-30 years) in patients without recurrence; 732 were followed for C10 years. There were 363 recurrences; 192 patients developed a DCIS ipsilateral breast recurrence. Of the 160 invasive recurrences, 147 were ipsilateral breast recurrence, 10 were concurrent breast and regional nodal recurrence, 2 had evidence of axillary recurrence only, and one had distant recurrence without evidence of locoregional recurrence or contralateral invasive disease. There were 11 cases of recurrence of unknown type, and distant disease developed in 19 patients, with 16/19 occurring after an invasive locoregional recurrence.
Differences in Patient, Tumor, and Treatment Characteristics by Age
Women \40 years of age constituted a smaller proportion of the population after 1999 compared with the earlier years of the study (3.8 vs. 7.1 %). Comparison across the age categories demonstrated that patients \40 years of age more frequently presented clinically than their older counterparts, and less frequently received adjuvant endocrine therapy. Women C70 years of age less frequently had three or more excisions, more frequently had positive or close margins, and less commonly received adjuvant RT or endocrine therapy.
Differences in Recurrence Rates by Age
With increasing age there was a significant decrease in 10-year recurrence rates, ranging from 7.5 % in women C80 years of age to 27.3 % in women \40 years of age (p \ 0.0001) (Fig. 1a) . After stratification by use of RT, the association of decreasing recurrence rates with increasing age persisted in those not receiving and those receiving RT (Fig. 1b, c) .
Our population included only women undergoing BCS. To exclude the possibility that the observed relationship between age and recurrence risk is due to treatment selection bias toward BCS among young women, we examined the proportion of patients undergoing BCS and mastectomy by age (electronic supplementary Fig. 2 ). The proportion of women undergoing BCS was correlated with age, with younger women more frequently undergoing mastectomy, thereby demonstrating that the observed association of young age and higher risk of recurrence is not due to underutilization of mastectomy in younger women.
Multivariable Analysis Multivariable analysis of 2634 patients with complete data was performed, adjusting for presentation, family history, necrosis, number of excisions, a v square test of difference between age at time of surgery margin status, adjuvant RT, adjuvant endocrine therapy, and treatment period. Grade was not significantly associated with age (p = 0.4) nor with recurrence on either univariate (p = 0.4) or multivariable (p = 0.9) analysis and was therefore not included in the final multivariable model (Table 2) . After adjustment for eight clinicopathologic and treatment variables, risk of recurrence remained significantly lower in older age groups, with decreasing hazard ratios (Table 2) .
Separate multivariable analyses of the 1163 women treated without RT and the 1471 who received RT were performed. Age was significantly associated with recurrence risk in both groups but the effect was most evident in women receiving RT (Table 2) .
Invasive Versus In Situ Recurrences
Because the implications of invasive and in situ recurrence differ, we examined them as competing risks according to age (Fig. 2) . Women \40 years of age were empirically at higher risk for invasive recurrence than DCIS recurrence (10-year invasive vs. DCIS risk: 15.8 vs. 11.5 %). In contrast, in all other age groups the risk of DCIS recurrence was at least as high as the risk of invasive recurrence. Ten-year risk estimates for invasive recurrence were 15.8 and 6.5 % for those aged \40 years and C40 years, respectively.
We also built a competing risk multivariable model to adjust for other clinicopathologic factors that vary by age or are associated with recurrence ( Table 3 ). The effect of age on risk of invasive recurrence was greater than the effect of age on overall recurrence or in situ recurrence. For both invasive and in situ recurrences, the use of RT was associated with an approximate 50 % reduction in the risk of recurrence (p B 0.00004).
Age and Risk of Distant Disease
Nineteen (0.6 %) patients ultimately developed distant disease (without contralateral invasive breast cancer). Women \40 years of age accounted for 21 % of these but constituted only 4.7 % of our population. This suggests that young women may be at higher risk of developing distant disease, which is consistent with the finding that younger women were at particularly high risk for invasive recurrence. Nonetheless, even among the youngest women \40 years of age, only 2.8 % developed distant metastases.
DISCUSSION
For almost 2 decades it has been recognized that age is associated with risk of recurrence for DCIS treated with BCS. In 1999, Van Zee et al. found that 6-year recurrence rates varied by age (47 %, \40 years; 14 %, 40-69 years; , and that the differences persisted when stratified by radiation use. 12 In 2000, Vicini et al. also reported that young age was a risk factor for recurrence among women who underwent BCS and RT; 10-year recurrence rates were 26 % in women\45 years of age versus 8.6 % in women C45 years of age (p = 0.03). 13 Cutuli et al. found that young age was associated with higher 7-year recurrence rates, but only in those treated with RT (29 %, B40 years; 13 %, 41-60 years; 8 %, C61 years) [p \ 0.001].
14 As results of the randomized studies of adjuvant RT or tamoxifen for DCIS became available, these findings were confirmed with prospective data. In 2001, Bijker et al. reported European Organisation for Research and Treatment of Cancer (EORTC) 10853 results at a median follow-up of 5.4 years; compared with age [40 years, age B40 years was associated with a twofold increased risk of recurrence (HR 2.14; p = 0.02) on multivariable analysis. 16 With 15.7 years of follow-up, Donker et al. confirmed these findings, with women B40 years of age having a higher risk of recurrence than those aged [40 years (HR 1.94; p = 0.009). 9 While National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 found no difference in recurrence rates between age groups (B49, 50-59, and C60 years) at a median follow-up of 7.5 years, 17 in NSABP B-24 older women were found to have a lower risk of recurrence at a median follow-up of 6.2 years (relative risk for C50 years of age vs. B49 years of age = 0.43; 95 % confidence interval 0.31-0.59). 18 In a combined analysis of B-17 and B-24 with long-term However, based on this literature, it is challenging to fully understand the relationship of age and recurrence risk because age categories have been variably defined and the extremes of age are underrepresented. Both retrospective and prospective randomized trials have used widely varying age categorization schemes. In the randomized trials, the youngest cohort was defined as B40 years of age (similar to our dataset) in the EORTC 10853 trial 9 and, in contrast, was defined as \52 years of age in the SweDCIS study. 7 The definition of the oldest age category has ranged from [40 years to C65 years. 8, 9 In addition, screening patterns limited the evaluation of the extremes of age; the SweDCIS and UK/ANZ trials primarily recruited from a screen-detected population C50 years of age. Overall, few younger women were included in the trials: SweDCIS, 35 women \40 years of age; EORTC 10853, 51 women 19 We sought to examine the relationship of age and recurrence across the full spectrum of age. Because of the large size of our series and the lack of exclusions, we were able to systematically describe recurrence rates by decade of age, thereby reflecting the actual age distribution of patients presenting with DCIS and undergoing BCS.
Women \40 and C70 years of age constituted 4.7 and 18 % of our population, respectively.
Our data not only demonstrate that the risk of recurrence after BCS for women with DCIS significantly decreases with age, but also that it appears to do so in a non-linear fashion. Those in the youngest group (\40 years of age) are at particularly high risk, while the eldest (C80 years of age) are at particularly low risk. These findings persisted when the cohorts that did and did not receive radiation were analyzed separately.
Numerous clinicopathologic factors have been found to influence the risk of recurrence of DCIS and many of them vary by age, thereby potentially confounding the association of age and recurrence. Because our population is large, well-characterized, and has significant follow-up, we were able to adjust for many factors that vary with age at diagnosis, thereby enabling us to assess the independent effect of age on recurrence. The relationship between age and recurrence risk persisted after controlling for other factors with multivariable analysis.
The overview of the randomized trials of radiation for DCIS noted that RT resulted in a larger proportional reduction in risk for women C50 years of age compared with women \50 years of age (HR 0.38 vs. 0.69; p = 0.0004). 6 Updated results from the SweDCIS and UK/ ANZ trials confirmed that there are age-related differences in the responsiveness to RT, with smaller proportional and absolute risk reduction from RT in younger women. 7, 10 We found that after stratification for RT use, the HR for recurrence decreased with age in both the RT and no RT cohorts, with the effect being more marked in the RT cohort; this observation is consistent with the finding of a greater benefit of RT with age.
The long-term outcome following an invasive recurrence is worse than after an in situ recurrence. [7] [8] [9] Data from EORTC 10853 and SweDCIS, as well as pooled data from the NSABP B-17 and B-24 trials, showed that young age was associated with higher risk for an invasive recurrence. [7] [8] [9] In our population, recurrences in women aged \40 years were more likely invasive than DCIS, in contrast to all other age groups in whom DCIS recurrences were at least as frequent as invasive recurrences (Fig. 2) . Furthermore, we found that the relationship between age and invasive recurrence risk was much stronger than that between age and DCIS recurrence. Compared with women aged C80 or 50-79 years, women aged \40 years had a sevenfold or threefold higher risk of developing an invasive recurrence, respectively. Narod et al. recently reported SEER data showing that women with DCIS had a 3.3 % 20-year breast cancerspecific mortality (including those who developed contralateral breast cancer), with women aged \ 35 years having a higher risk of breast cancer-specific mortality than older women (HR 2.58; p \ 0.001). 11 Our population also had an excellent distant disease-free survival, with only 19 (0.6 %) women, without contralateral invasive cancer, ultimately developing distant metastasis. While the number of distant events in our population is too small to perform a formal analysis, our finding that women \40 years of age are at particularly high risk for invasive recurrence and are overrepresented among those who did ultimately develop distant disease (4 of 19) is consistent with the observation of higher mortality among young women with DCIS. It is important to note that there were only three cases (0.1 %) of distant metastases in the absence of invasive local recurrence or contralateral invasive breast cancer, supporting the importance of maintaining local control in these patients.
The association between age and risk of recurrence should be incorporated into a thorough discussion with a woman regarding the various treatment options, including the relative importance to that individual woman of the various risks and benefits of each option. Given that there is no evidence of a survival advantage with or without RT, or with BCS or mastectomy, and given that the quality of life implications-both psychological and physical-of various treatment options will vary in different women, we believe that the optimal approach is to provide risk estimates that are as accurate as possible. We have previously developed a nomogram 20 (available at www.nomograms.org), now validated in at least four different independent populations, [21] [22] [23] [24] that incorporates age and provides a risk estimate for an individual woman. A careful discussion with the patient can then help her weigh the risks and benefits and their relative value for her, in order that she can make the best decision for herself.
CONCLUSIONS
Risk of recurrence following BCS for DCIS decreases with age. This effect is particularly strong at the extremes of age, and persists even after controlling for other clinicopathologic and treatment factors. This finding remained true in cohorts that were treated with and without RT. The oldest women are at low risk of recurrence; the youngest have a higher overall, and especially invasive, recurrence rate, although mortality remains low. These findings should inform discussions in patients presenting with DCIS and be incorporated into risk/benefit considerations for surgical planning and adjuvant treatments.
